EISSN 2148-5607

TJG IS INDEXED IN SCI-EXPANDED AND PUBMED IMPACT FACTOR: 1.4

Turkish Journal of Gastroenterology

35 414 2024

HIGHLY CITED ARTICLES

HBV and HCV are the risk factors in CCA

Tan et al.

Serum resolvin levels in irritable bowel syndrome

Karatay and Gül Utku

Microbial improvement after intervention

Qian et al.

18F-FDGPET/CT in gallbladder carcinoma

Arslan et al.

Bezoar in endoscopy

Gökbulut et al.

Effect of vitamin D on CD40L gene expression in UC

Sharifi et al.

ERCP for acute cholangitis

Khamaysi and Taha

Inborn metabolic causes of fatty liver disease

Yıldız and Sivri

Gastric and small intestinal TSA

Kiremitci et al.

COVID-19 in Hepatology and Liver transplantation

Kabaçam et al.

Submission to First Decision = 31 Days

Author’s Reply

RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy

İlkay Ergenç ¹ , Haluk Tarık Kani ¹ , Murat Karabacak ² , Elif Cömert Özer ³ , Shahin Mehdiyev ¹ , Fuad Jafarov ¹ , Kerem Yiğit Abacar ² , Seda Kutluğ Ağaçkıran ² , Gizem Sevik ² , Rahmi Aslan ¹ , Fatma Alibaz Öner ² , Nevsun İnanç ² , Mehmet Pamir Atagündüz ² , Dilek Seçkin ³ , Yeşim Özen Alahdab ¹ , Tülin Ergun ³ , Haner Direskeneli ² , Özlen Atuğ ¹

Author Affiliation(s)

1.

Department of Internal Medicine, Division of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkey

2.

Department of Internal Medicine, Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

3.

Department of Dermatology, Marmara University, School of Medicine, Istanbul, Turkey

Turk J Gastroenterol 2023; 34: 310-310

DOI: 10.5152/tjg.2023.237002

Read: 1140 Downloads: 406 Published: 01 March 2023

Volume 34, Issue 3, March 2023

Previous Article

Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. RE: risk of HBV reactivation in HBsAg negative and anti-HBc IgG positive patients receiving biologic therapy. Turk J Gastroenterol. 2023;34(3):310.

Files